1. Home
  2. INDV vs EWTX Comparison

INDV vs EWTX Comparison

Compare INDV & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Indivior PLC

INDV

Indivior PLC

N/A

Current Price

$35.64

Market Cap

4.2B

Sector

Health Care

ML Signal

N/A

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

N/A

Current Price

$38.46

Market Cap

4.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
INDV
EWTX
Founded
1994
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
4.3B
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
INDV
EWTX
Price
$35.64
$38.46
Analyst Decision
Strong Buy
Buy
Analyst Count
4
14
Target Price
$49.50
★ $52.62
AVG Volume (30 Days)
★ 2.2M
1.2M
Earning Date
10-29-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 8100.00
N/A
EPS
★ 2.78
N/A
Revenue
★ $1,239,000,000.00
N/A
Revenue This Year
$7.50
N/A
Revenue Next Year
$5.07
N/A
P/E Ratio
$12.59
★ N/A
Revenue Growth
★ 4.29
N/A
52 Week Low
$27.68
$16.70
52 Week High
$42.81
$48.51

Technical Indicators

Market Signals
Indicator
INDV
EWTX
Relative Strength Index (RSI) 53.02 43.36
Support Level $32.90 $37.33
Resistance Level $35.93 $41.13
Average True Range (ATR) 1.41 1.83
MACD 0.12 0.18
Stochastic Oscillator 68.87 44.67

Price Performance

Historical Comparison
INDV
EWTX

About INDV Indivior PLC

Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.

Share on Social Networks: